Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Julia Scarisbrick et al.|The Lancet|2017Cited by 580
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 TrialR. Willemze, Théo de Witte, Stefan Suciu et al.|Journal of Clinical Oncology|2013Cited by 168